Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

NCT00493467 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Ibritumomab Tiuxetan (Zevalin)
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]